13 Jul

The Key to Increasing Patient Retention in Clinical Trials

With 85% of clinical trials experiencing delays [1], any opportunity to keep a trial on track can save a study money, time, and resources.

There are a lot of reasons a trial can be derailed, with poor patient retention being among one of the biggest struggles.

It is natural for some patients to drop out, as study participation is voluntary. However, identifying the common reasons for participant drop out helps sponsors to address these issues to increase the patient retention rate.

Why do patients drop out?

The first thing to address is: why do patients drop out in the first place?

Some common reasons for participant drop out include:
- Location of the site
- Scheduling conflicts
- Personal reasons
- Lack of effective communication from the PI
- Fear and anxiety
- Unmet expectations

Some of these are out of a sponsor’s control, and any trial should be prepared to deal with a certain amount of dropouts that may simply come down to a participant changing their mind . However, sponsors can minimise reasons such as fear and anxiety by establishing effective communication, clear expectations, and accessible location of the site prior to the recruitment process.

Patient Centricity
Patient recruitment outcomes are driven right from the start of the trial. This means that developing a patient centric protocol design is essential for recruitment and retention.

A patient centric trial is centred around the voice and the needs of the patient, making the study attractive and easy for participants.

Proactively engaging with patients is one the most important aspects of a patient centric trial. With scheduling conflicts being one of the most common reasons participants drop out, accommodating for their lifestyle while scheduling appointments should be an important consideration. Some examples of how this can be incorporated include scheduling appointments for working patients over the weekends while booking earlier appointments for the older patients.

There won’t be one ideal time for everyone, so it’s also essential for sponsors to allow for flexibility. This has become evident in the COVID-19 world as the development of telehealth, and virtual trial technologies has benefited those unable to travel while also assisting participants who struggle with getting to trial sites.
Since the pandemic began, participants have become warier of travel and participating in clinical trials for fear of exposure to the virus. Virtual trials minimise this fear and anxiety by eliminating the threat of COVID-19 transmission through in-face trial site visits.

Selecting a site

Patient experience should be a priority during the site selection process of a clinical trial.
A survey found that 38% of patients who dropped out of a trial said it was because the site visits were ‘stressful’ [2]. Sites that have also adopted a patient centric attitude will likely be able to retain patients better than those who don’t.

Having a friendly, professional environment, clear communication, and even free parking can significantly impact patient retention.

Phillippa Murray of Lakeland Clinical Trials Group says, “We have found our new site location with onsite car parking has made an enormous difference to our patient visits. We have 100% attendance to onsite visits. Patients also comment on how available our investigators are to them, especially the Principal Investigator.”

Choosing your trial’s location

Where a clinical trial is run can also determine patient retention.

In Australia and New Zealand, there is a strong willingness to participate in clinical trials. Trial stats from ANZCTR show that between 2015 and 2020, patient recruitment exceeded expectations, resulting in 103% retention of patients [3]. This has been a combination of efforts put in by the Australia Government and a highly informed, willing, and ethically diverse patient population spread across both regions.

The relatively low transmission rates of COVID-19, particularly in New Zealand, means the population is not as fearful of contracting the virus and therefore more inclined to participate in studies.

Even with there being less risk to exposure to COVID-19 in New Zealand, telehealth capabilities and virtual trial technologies were adopted early into the pandemic and have been widely embraced in this region. Our remote monitoring SOPs take into consideration the safety of the sites, patients, and staff, while also ensuring the continuity of trials.

By establishing clear processes that directly address the needs of participants, sponsors are thereby showing their appreciation for patients' participation.

PharmaSols recognises the importance of building processes based on a patient centric attitude. Our people-driven team is dedicated to delivering participant recruitment and retention targets.

[1] Facts about clinical trials. (Online) Available at: http://www.arena-international.com/clinicaltrials/facts-about-clinical-trials/1063.article (Accessed 07/07/2021)
[2] Retention in Clincial Trials: Keeping Patients on Protocols (Online) Available at: https://www.advarra.com/resource-library/retention-in-clinical-trials-keeping-patients-on-protocols/?swpmtx=ed651b04db65b0b1ef8e082dbbee1837&swpmtxnonce=e3e8a38eeb (Accessed on 07/07/2021)
[3] Australia New Zealand Clinical Trials Register (2015-2020) Commercial Trials

Other News

HiRO: Just One of the Heroes in Clinical Research Management

You’ve probably heard it said before: people are the greatest assets. A company that fails to recognise the value of their people miss the greatest opportunities for success and future growth.

Read more
How To Prevent Clinical Drug Trial Delays

Delayed clinical drug trials are a thorn in the side of any study stakeholder. This blog will discuss at the main causes of delayed trials, and what precautions can be taken to ensure timelines can be adhered to.

Read more
How Does Rapid Start Up Affect Clinical Trials?

Fast, efficiently run trials benefit from gaining a competitive edge, a good reputation and credibility amongst stakeholders, as well as a period of exclusivity if the product is the first to be introduced to market.

Read more